- Home
- NVX vs EDIT Comparison
NVX vs EDIT Comparison
Compare NVX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- EDIT
- Stock Information
- Founded
- NVX 2012
- EDIT 2013
- Country
- NVX Australia
- EDIT United States
- Employees
- NVX N/A
- EDIT N/A
- Industry
- NVX Industrial Machinery/Components
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVX Miscellaneous
- EDIT Health Care
- Exchange
- NVX Nasdaq
- EDIT Nasdaq
- Market Cap
- NVX 176.8M
- EDIT 179.1M
- IPO Year
- NVX N/A
- EDIT 2016
- Fundamental
- Price
- NVX $1.10
- EDIT $2.88
- Analyst Decision
- NVX
- EDIT Buy
- Analyst Count
- NVX 0
- EDIT 12
- Target Price
- NVX N/A
- EDIT $6.20
- AVG Volume (30 Days)
- NVX 59.8K
- EDIT 3.5M
- Earning Date
- NVX 01-01-0001
- EDIT 08-06-2025
- Dividend Yield
- NVX N/A
- EDIT N/A
- EPS Growth
- NVX N/A
- EDIT N/A
- EPS
- NVX N/A
- EDIT N/A
- Revenue
- NVX $5,854,424.00
- EDIT $35,837,000.00
- Revenue This Year
- NVX $66.66
- EDIT N/A
- Revenue Next Year
- NVX $2,366.64
- EDIT N/A
- P/E Ratio
- NVX N/A
- EDIT N/A
- Revenue Growth
- NVX N/A
- EDIT N/A
- 52 Week Low
- NVX $0.81
- EDIT $0.91
- 52 Week High
- NVX $2.73
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- NVX 46.92
- EDIT 74.64
- Support Level
- NVX $1.06
- EDIT $2.48
- Resistance Level
- NVX $1.21
- EDIT $3.24
- Average True Range (ATR)
- NVX 0.06
- EDIT 0.25
- MACD
- NVX 0.01
- EDIT 0.07
- Stochastic Oscillator
- NVX 42.14
- EDIT 84.84
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.